Pharmaceuticals, Biotechnology and Life Sciences
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall…
Medigene has reported its financial performance in the third quarter of 2023 was in line with the Executive Management Board’s expectations, as the revenues in the third quarter 2023 amounted to EUR 1.6 million compared to EUR 1.4 million in the previous year period (9-month period 2023: EUR 4.6 million), primarily from the partnership with BioNTech.
BioNTech is evaluating the potential impact of Pfizer’s write-offs and other charges related to COMIRNATY on its financial results.
BioNTech and US based OncoC4 today announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart). The trial is part of BioNTech’s strategy to initiate multiple pivotal trials in 2023 and 2024, the companies said in a press release Thursday.
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of Pfizer BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.
Collaboration leverages BioNTech’s multi-platform immunotherapy capabilities and Medigene’s T cell receptor (TCR) discovery platform to discover and develop innovative TCR…
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data…
New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine.